Business context and reporting period
This is Sunshine Heart, Inc.’s unaudited Form 10-Q for the three months ended March 31, 2014—not a filing under the name Nuwellis. Sunshine Heart was developing the C-Pulse System, an implantable heart-failure therapy. The system was not approved for U.S. commercial sale; reported sales came from clinical-study sites.
Financial results and liquidity
Amounts are in U.S. dollars; financial statement figures are in thousands except per-share data.
- Revenue: $59,000, versus none in Q1 2013, from one clinical-study device implantation. Revenue was minimal and not representative of commercial sales.
- Expenses and losses: Operating expenses were $6.424 million (SG&A $2.361 million; R&D $4.063 million), up from $4.402 million. Operating loss was $6.365 million; net loss was $6.332 million, compared with $4.399 million a year earlier. Loss per share was $0.38 versus $0.47; weighted-average shares rose to 16.859 million from 9.417 million.
- Margins: The filing does not provide a meaningful gross margin; clinical-study product costs were expensed as R&D.
- Cash flow: Operating cash use was $6.687 million, versus $4.114 million. Investing cash use was $46,000; financing provided $16,000. Cash declined $6.715 million to $47.421 million.
- Balance sheet: Current assets were $48.304 million and current liabilities $2.667 million. Total liabilities were $2.667 million; no borrowings or interest-bearing debt are reported. Stockholders’ equity was $46.209 million.
- Other metrics: Accumulated deficit was $107.344 million. Stock-based compensation expense was $735,000, included in operating expenses.
Material changes versus Q1 2013
- R&D expense increased 67.5%, primarily due to additional personnel and clinical-research infrastructure supporting North American and European studies.
- SG&A increased 19.5%, reflecting infrastructure and higher equity compensation costs.
- Net loss increased by $1.933 million, while loss per share narrowed because weighted-average shares increased substantially.
- Operating cash use rose by $2.573 million. Financing proceeds declined to $16,000 from $874,000.
Outlook, risks and notable items
- Management expected losses for the foreseeable future and said R&D and SG&A would remain above prior-year levels during 2014. Revenue was expected to remain minimal until pivotal-study enrollment increased and European reimbursement was established.
- The company had FDA authorization to conduct a U.S. pivotal study, which began enrolling in Q3 2013; a European post-market study began enrollment in Q2 2013. The company also held CE Mark approval.
- Going concern: Continued operations depended on raising additional capital and successfully developing and commercializing the product. Management believed it could raise equity as needed, but gave no assurance; failure to secure funding could threaten continuation as a going concern.
- Key risks included clinical and regulatory outcomes, market acceptance, and access to additional capital. Further equity financing could dilute shareholders; debt financing could impose senior claims and restrictive covenants.
- No material legal proceedings, material capital-expenditure commitments, or off-balance-sheet arrangements were reported. Management concluded disclosure controls were effective at a reasonable assurance level.
Important facts for investors to verify
- Confirm the filing entity and period: Sunshine Heart, Inc., quarter ended March 31, 2014.
- Review subsequent clinical-trial enrollment, safety and efficacy results, and regulatory milestones for C-Pulse.
- Assess cash burn against the $47.4 million quarter-end cash balance and the company’s ability to raise additional capital.
- Verify whether commercialization and reimbursement assumptions translated into recurring revenue; Q1 sales were only $59,000 from one implantation.
- Consider potential dilution: 3.512 million options, warrants and restricted stock units were excluded from diluted loss per share as anti-dilutive.